The timely initiation of tumor necrosis factor (TNF) blocking agents plays a critical role in the successful management of spondyloarthropathies by substantially reducing disease activity, leading to improved symptoms and radiographic sacroiliitis outcomes [77-79]. This evidence concerns the gene TNF and spondyloarthropathy.